Toggle light / dark theme

Theme: Lifelong Brain Development.

Abstract: The human brain sets us apart as a species, with its size being one of its most striking features. Brain size is largely determined during development as vast numbers of neurons and supportive glia are generated. In an effort to better understand the events that determine the human brain’s cellular makeup, and its size, we use a human model system in a dish, called cerebral organoids. These 3D tissues are generated from pluripotent stem cells through neural differentiation and a supportive 3D microenvironment to generate organoids with the same tissue architecture as the early human fetal brain. Such organoids are allowing us to tackle questions previously impossible with more traditional approaches. Indeed, our recent findings provide insight into regulation of brain size and neuron number across ape species, identifying key stages of early neural stem cell expansion that set up a larger starting cell number to enable the production of increased numbers of neurons. We are also investigating the role of extrinsic regulators in determining numbers and types of neurons produced in the human cerebral cortex. Overall, our findings are pointing to key, human-specific aspects of brain development and function, that have important implications for neurological disease.

About this series: The Cambridge Neuroscience Interdisciplinary Seminar Series provides a forum for neuroscientists across Cambridge and beyond to discuss contemporary and interdisciplinary research topics and issues.

The seminars are open to both members of the University, external academics and members of the public. We have tried to reflect the diversity of people’s interests at the University with our programme, and the breadth of the research taking place in Cambridge. Registration and more details are available here: http://talks.cam.ac.uk/show/index/125062

UCLA Broad Stem Cell Research Center member Ranmal Samarasinghe, MD, PhD presents his work using brain organoids to create better models of neurological disorders. An Assistant Professor in UCLA’s Neurology department, Dr. Samarasinghe splits his time between the clinic, seeing patients who have neurological conditions like epilepsy and autism, and in the lab working to create more detailed disease models using brain organoids. In this video, Dr. Samarasinghe discusses how brain organoids are becoming more sophisticated in their ability to replicate irregular brain wave patterns seen in conditions like Rett syndrome, an epilepsy primarily associated with infants. Ultimately, he hopes these stem cell-based models can be used to screen new drugs and discover new treatments for diseases like epilepsy.

Learn more about Dr. Samarasinghe’s work here:
https://stemcell.ucla.edu/member/sama… the full “The Power of Regenerative Medicine: Future Treatments for Brain Disease” webinar: • The Power of Regenerative Medicine: F…

Watch the full \.

While these are two separate chronic conditions, they are linked as about one in every three adults with type 2 diabetes also has chronic kidney disease.

Additionally, both conditions are associated with an increased risk for cardiovascular complications such as stroke and heart attack.

The BCI is rapidly evolving, but the real challenge has always been the long-term usability of devices implanted in the brain. Because of this, it is exciting to see the early success stories of Neuralink with the three patients who have received chip implants so far. They have all achieved results beyond expectations without any risks, which has made Elon Musk even more confident and ambitious with his implanted chip. He has decided to upgrade the chip to a higher level to support more people with disabilities. At the same time, Musk has shared updates on the condition of the three Neuralink-implanted patients. This year, the number of implant recipients is expected to increase significantly. So, is this a major turning point for people to trust Neuralink? Explore the latest updates now, Welcome to Tesla Car World!

Full NEURALINK Human Trials! Elon Musk Reveals NEW Updates On Three Patient Shocking In 2025! You may not believe it, but from the perspective of many people, Neuralink is one of Elon Musk’s most controversial and ridiculous companies. They argue that Musk should focus on Tesla and SpaceX instead of a less widely accepted field like BCI. Concerns about the dangers of implanting chips in the brain, especially given how new this technology is, remain a hot topic of discussion. Some even fear that brain data could be misused or compromised if Neuralink were hacked. However, despite these concerns, it is undeniable that for the three implanted patients, Neuralink means more than ever. They seem to be living a second life, in fact, Neuralink makes them feel as if they have been reborn.

Full NEURALINK Human Trials! Elon Musk Reveals NEW Updates On Three Patient Shocking In 2025! Imagine losing the ability to move, communicate, or control your own body. Then, one day, something allows you to think and control a computer cursor, communicate with the world through your thoughts, and do things you had once given up hope on. For the three patients who have experienced Neuralink, this is not just an ordinary chip, it is an opportunity, a hope, a real-life miracle.
===
#888999evs #teslacarworld #teslacar #888999 #teslaneuralink #neuralink.
subcribe: https://bit.ly/3i7gILj

Health, vitality and longevity through bioengineering — kevin caldwell — CEO, ossium health.


Kevin Caldwell is CEO, Co-Founder & President of Ossium Health (https://ossiumhealth.com/), a commercial stage bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects.

Mr. Caldwell built Ossium from a small startup into the clinical stage bioengineering company it is today, setting the company’s mission to improve human health through bioengineering and designed its platform-based model for cellular therapeutics development. He has led the company’s successful pursuit, negotiation, and execution of more than 50 business relationships, including 5 successful fundraisings and dozens of supply partnerships, clinical partnerships, and commercial contracts with biopharmaceutical companies.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Chemistry researchers at Case Western Reserve University have identified specific markers that could pave the way for new blood tests to detect diseases.

Almost every disease involves some degree of inflammation, yet standard blood tests cannot precisely identify which organs or tissues are affected.

Now, researchers at Case Western Reserve University have developed an antibody-based method to detect inflammation, which could pave the way for blood tests that identify disease-specific biomarkers. This advancement has potential applications in diagnosing conditions such as heart disease, Alzheimer’s.